Vimarsana
Biggest News Aggregation in the World

Functional Defecation Disorders News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Functional Defecation Disorders. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Functional Defecation Disorders Today - Breaking & Trending Today

Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation - Vimarsana News

Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation

Published: January 9, 2024

– Newly published data highlights additional efficacy endpoints from trial – – Linaclotide is the first and only FDA-approved prescription therapy for children and adolescents aged 6-17 years...

Source: marketscreener.com
Related Topics:
United StatesGeorgee BatchelorIronwood Pharmaceuticals NasdaqJerome FoundationUniversity Of Miami Health SystemUniversity Of MiamiIronwood Pharmaceuticals IncNational Population Projection TablesDrug AdministrationDivision Of Pediatric GastroenterologyIronwood PharmaceuticalsLancet GastroenterologyMiguel SapsPediatric GastroenterologyEndowed ChairMiami HealthCommon Adverse ReactionsPrescribing InformationBoxed WarningChildhood Functional Gastrointestinal DisordersFunctional Gastrointestinal DisordersPopulation Projection TablesFunctional Defecation DisordersSystemic Review
Ironwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old - Vimarsana News

Ironwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old

Published: June 12, 2023

– LINZESS is the first and only FDA-approved prescription therapy for functional constipation in this patient population – – Approval brings a much-needed option to an estimated 6... | June 12, 2023

Source: marketscreener.com
Related Topics:
United StatesCecielt RookerNational Population Projection TablesInternational Foundation For Gastrointestinal DisordersIronwood Pharmaceuticals IncIronwood PharmaceuticalsDrug AdministrationIronwood Pharmaceuticals NasdaqJerome FoundationNew Drug ApplicationInternational FoundationSerious DehydrationPediatric Patients Less ThanAbout IronwoodAnnual ReportPopulation Projection TablesFunctional Defecation DisordersSystemic ReviewChildhood Functional Gastrointestinal DisordersFunctional Gastrointestinal DisordersNc Stock ExchangePress ReleaseStimated Irwd Us46333x1081